INPI United States

L'INPI est un établissement public, entièrement autofinancé, placé sous la tutelle du ministère de l'Économie, de l'Industrie et du Numérique.

Il délivre les brevets, marques, dessins et modèles et donne accès à toute l'information sur la propriété industrielle et les entreprises.

Il participe activement à l'élaboration et à la mise en œuvre des politiques publiques dans le domaine de la propriété industrielle et de la lutte anti-contrefaçon.

Dr Leila Equinet
IP counselor 

Institut Pasteur United States

Dr Jean-Loup Romet-Lemonne
LinkedIn logo Senior Advisor Global Development 

Institute for Life Sciences Collaboration United States

At ILSC, we believe that collaboration and innovation are the best ways to tackle the world’s most pressing health challenges. As a result, we strive to encourage and enhance the development of innovative initiatives and collaborative approaches. To achieve our mission, we have formed strong partnerships with leading experts, academic institutions, organizations, and key stakeholders, including Yale UniversityIBMUNA-USACIMIT, and the Climate Remediation Foundation. Through our collaborations, we aim to make meaningful and measurable improvements in the global healthcare landscape.

Aaron Etra
LinkedIn logo , Secretary & Treasurer 

Integrative Center for Wellness United States

Provides psychiatric and wellness services to individuals seeking a healthy balance between mind and body. With an ever-increasing amount of medical research now linking brain chemistry with physical health, we strongly support a holistic approach to healthcare that integrates psychiatric and nutritional treatments and emphasizes whole-body wellness.

The founder of the Center is a psychiatrist with an extensive background in internal medicine. He has over twenty years of experience treating patients in the New York City area.

Ms Kimberly Macleod

Integrative Center for Wellness United States

Dr. Ahmad’s clinical philosophy reflects the wisdom of the Greek physician Hippocrates: it is more important to know what person the disease has than what disease the person has.

“Our bodies are a unique function of both our genetics and our environment. I am committed to understanding each individual’s differences, getting to know the patient behind the illness, and providing the best treatment with therapy, medication and nutrition.”

Samoon Ahmad, MD

Dr Samoon Ahmad
LinkedIn logo Founder, Physician 

Intellitech France

Intellitech Robust Predictive Modeling of Complex Processes based on an Intelligent Analysis of Big / Smart Data Industry sectors Other: Predictive Me Therapeutics Area Cardiology / Vascular Diseases
Dental and Oral Health
Gastroenterology / Hepatology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pulmonary/Respiratory Diseases
Rare Disease
Your innovative solution

Our xtractis' robot incorporates the latest advances in Artificial Intelligence, especially Fuzzy Logic and Machine Learning. It analyses a multidimensional database and automatically discovers robust fuzzy rule-based Decision Support Systems which are able to predict with the most reliability the complex process under study.

Which problem are you solving ?

Robust Predictive Models for Epigenetics Personalized Medicine and Pharmacogenomics: Drug Discovery (efficiency, toxicity), Early Diagnosis, Companion Diagnostic, Virtual Screening, Selection of Best Target Patients, Disease Evolution, Survival Duration, Preventive Care, Environmental/Life-style/Diet/Therapeutic Recommendations, Side Effects & Adverse Events, Protein Homology, Reimbursement Rate of a Drug, Insurance Risk Scoring of a Patient

Target market segments

Pharmaceutical Industry / Personalized Medicine Diagnostics / Hospitals & Medical Centers / Private or Public Insurers

Key value proposition

Unique mathematical approach (fuzzy, possibilistic, inductive, automatic, holistic, non-linear, non-monotonic, without a priori) / Proprietary algorithms implemented in fully automated software with user-friendly MMI / Better predictive capacity (robustness) vs. prevailing world-class techniques / Handles weak signals and low quality data

Prof. Zyed ZALILA
President and CEO 

International American Capital Inc. United States

International American Capital Inc. (IAC), an Affiliate of the SCS Group, is a full service independent corporate and family consulting firm. IAC has a long standing tradition dedicated to wealth management for institutions and families. This focus allows us to achieve the highest level of expertise and excellence. IAC is independent advisory firm, free of any conflicts of interest that may arise in larger financial institutions. IAC  enjoys total financial independence and complete autonomy in the decision making process. We therefore offer our clients independent, trusted unbiased advise.  

The principals if IAC have over 70 years of experience in the financial services industry. IAC is led by entrepreneurs. As such, we have a better understanding of our clients' needs and expectations. The flexibility and availability of its principals to all our clients enables IAC to respond rapidly to customized solutions. Our principals are currently licensed with the SEC, FINRA and the CFTC. he CFTC. 
Mr Michael Segal

Intl law. United States

LinkedIn logo Avocat à la Cour, Paris Licensed Legal Consultant, New York Référent du Barreau de Paris à New York / Representative of the Paris Bar in New York 

Intrexon Corporation United States

Intrexon applies engineering principles to biology to enable products in the health, food, energy, consumer and environmental industries.  Utilizing our advanced technologies, we work with researchers, developers and marketers to design, create or modify molecules, cells, organisms and processes to solve important problems in the living world.

Olivier Jarry
SVP Consumer Sector 

Ipsen Bioscience, Inc. United States

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology / Dysport®, endocrinology / Somatuline® and uro-oncology / Decapeptyl®. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. The Group has close to 4,600 employees worldwide. 

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, and

Dr Girish Aakalu
Vice President Scientific Affairs, North America